Semi-Annual Statement Of Income And Retained Earnings

Daito Pharmaceutical Co., Ltd. - Filing #7545245

Concept 2022-06-01 to
2023-05-31
2022-06-01 to
2023-05-31
2022-06-01 to
2023-05-31
2022-06-01 to
2023-05-31
2022-06-01 to
2023-05-31
2021-06-01 to
2022-05-31
2021-06-01 to
2022-05-31
2021-06-01 to
2022-05-31
2021-06-01 to
2022-05-31
2021-06-01 to
2022-05-31
Semi-annual statement of income and retained earnings
Statement of income and retained earnings
Operating profit (loss)
5,207,000,000 JPY
5,023,000,000 JPY
6,553,000,000 JPY
5,979,000,000 JPY
Non-operating income
Non-operating income
86,000,000 JPY
149,000,000 JPY
205,000,000 JPY
288,000,000 JPY
Non-operating expenses
Non-operating expenses
124,000,000 JPY
89,000,000 JPY
29,000,000 JPY
27,000,000 JPY
Ordinary profit (loss)
5,169,000,000 JPY
5,082,000,000 JPY
6,729,000,000 JPY
6,240,000,000 JPY
Extraordinary income
Extraordinary income
12,000,000 JPY
12,000,000 JPY
269,000,000 JPY
276,000,000 JPY
Extraordinary losses
Extraordinary losses
105,000,000 JPY
229,000,000 JPY
278,000,000 JPY
255,000,000 JPY
Profit (loss) before income taxes
5,076,000,000 JPY
4,866,000,000 JPY
6,720,000,000 JPY
6,262,000,000 JPY
Income taxes - current
1,595,000,000 JPY
1,408,000,000 JPY
2,213,000,000 JPY
1,989,000,000 JPY
Income taxes - deferred
-46,000,000 JPY
-34,000,000 JPY
-120,000,000 JPY
-138,000,000 JPY
Profit (loss)
3,527,000,000 JPY
3,491,000,000 JPY
3,491,000,000 JPY
3,491,000,000 JPY
3,491,000,000 JPY
4,412,000,000 JPY
4,627,000,000 JPY
4,412,000,000 JPY
4,412,000,000 JPY
4,412,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.